Susan Bal Profile
Susan Bal

@SusanBal9

Followers
1K
Following
4K
Media
87
Statuses
707

Plasma Cell Disorders; Tx/Cell Therapy Physician @ UAB Medicine via Memorial Sloan Kettering; U of Cincinnati & Kettering; Tweets=My opinions #mmsm

Birmingham, AL
Joined March 2017
Don't wanna be here? Send us removal request.
@SusanBal9
Susan Bal
7 months
Thank you for the invitation @szusmani and Sham Mailankody to join this fantastic meeting, really great presentations and discussion.
@VJHemOnc
VJHemOnc
7 months
We're so excited to be at the inaugural #iwGPRC5D2025 Workshop! We'll be hearing about all things related to GPRC5D-targeted myeloma therapies - stay tuned for more. Chaired by @szusmani & Sham Mailankody #MMsm #HemOnc
0
2
7
@SusanBal9
Susan Bal
7 months
The funnest talk from @JoshuaRichterMD and a new acronym for neurotoxicity with gprc5d #iwgprc5d2025
2
4
25
@SusanBal9
Susan Bal
7 months
Practical tips from @RahulBanerjeeMD #iwgprc5d2025 on managing skin and nail toxicities
0
5
24
@SusanBal9
Susan Bal
7 months
Thank you for sharing and thanks to @TheLancetHaem for the opportunity to pen this commentary on an important update of a major practice informing - monumental study
@NorthTxMSG
Yelak Biru
8 months
Monumen-TAL progress in the treatment of relapsed multiple myeloma - Ongoing drug development of novel agents and deployment of innovative combinations remains paramount in chasing the elusive cure The Lancet Haematology https://t.co/AawuOM0ikc #mmsm
1
4
14
@SusanBal9
Susan Bal
1 year
We showed identical MRD responses as Quadruplet+ASCT and were able to spare a quarter of patients the toxicity of ASCT. Important to follow long term outcomes but so far so good! Larger studies Master-2 and MIDAS if further answer this and other important qs. But it can be done!
1
3
14
@SusanBal9
Susan Bal
1 year
At #IMS2024 we shared the first results from a pilot study of real time MRD-adapted deferral of ASCT in #mmsm absolutely could not have done this without the support of @End_myeloma and our fantastic MM team @uabmedicine
3
7
40
@SusanBal9
Susan Bal
1 year
No pressure right! Debating @Myeloma_Doc
@DrKrinaPatel
Krina Patel
1 year
Amazing debate by @Myeloma_Doc and @SusanBal9 about which antigen to use post BCMA Rx: BCMA versus other? #GDUHem
1
1
10
@SusanBal9
Susan Bal
1 year
Thanks @GKaurMD for the amazing kebabs delivered since she couldn’t take me out while in Dallas, the sweetest 🥹🫠
1
1
26
@SusanBal9
Susan Bal
2 years
Imp manuscript from the Mayo group @ZanwarSaurabh showing the outcomes of pts w/ suboptimal response to DaraVCd in NDAL. I have traditionally switched to BCL2 inhibition ASAP if t(11;14) but for the rest such a tricky spot! Hopeful for TCE in this popn https://t.co/TRPnSuZhQV
1
8
25
@SusanBal9
Susan Bal
2 years
Wonderful morning discussing the importance of MRD in high risk MM especially on the heels of the ODAC
@UrviShahMD
Urvi Shah
2 years
#DukeDebates in #mmsm @SusanBal9 vs Dr Raymond Thertulien on induction and MRD for high risk Dr Cristiana Chase vs Dr Taewoong Choi on CAR T vs transplant in relapsed MM
0
2
13
@SusanBal9
Susan Bal
2 years
Always great to listen to my previous co-fellow @UrviShahMD talk passionately about nutrition and myeloma
2
3
22
@SusanBal9
Susan Bal
2 years
Excellent thread on cilta-cel, only point I would highlight is if you progress on bridging therapy, your risk of fatal outcome 🔝 and in that situation I would not proceed directly with cilta cel but consider other options to lower disease burden!
@HadidiSamer
Samer Al Hadidi, MD,MS,FACP
2 years
#mmsm How to counsel patients about Cilta Cel using the data from CARTITUDE-4 and FDA ODAC meeting for earlier use With data of Cilta cel and Ide cel, assuming having access to both for a given patient, I will personally chose Cilta cel (I explained this before) 🧵
2
4
22
@SusanBal9
Susan Bal
2 years
When we presented this at EHA, less apparent but important to await data from additional patients and f/u at RP2D
@JanakiramMurali
Murali Janakiram
2 years
Interesting kinetic profile of GPRC5D CART cells- (n=26) hence preliminary - biphasic ? - higher median at 6 months than ide-cel ( will this persistence translate to longer PFS ) (Sadly all cilta-cel articles are behind a paywall @JanssenUS ) #ASH23
1
1
6
@SusanBal9
Susan Bal
2 years
And our fantastic CoMMiT and @uabmedicine team @End_myeloma @DholariaMD @nsc_natalie @GiraltSergio
1
2
8
@SusanBal9
Susan Bal
2 years
Fantastic time as always connecting with friends, mentors sharing and learning amazing science @ASH_hematology @NBahlis @kordeneha1 @OmarNadeemMD Dr. Zelenetz
1
2
15
@SusanBal9
Susan Bal
2 years
Encouraging early data showing IMiDs and possibly CelMODs can improve on the response to immunotherapy @MileHighMyeloma @End_myeloma
0
1
7
@SusanBal9
Susan Bal
2 years
Glorious skies, thick crowds and ready for @ASH_hematology Run
0
1
11
@SusanBal9
Susan Bal
2 years
Applaud the massive effort @mtmdphd undertakes every year to give us a glimpse of the best of #mmsm at @ASH_hematology and grateful to be included on this list!
@mtmdphd
Mike Thompson, MD, PhD, FASCO
2 years
Myeloma / Plasma Cell Dyscrasia ~ #ASH23Top10 (or so) #mmsm #mmMRD #ASH23 - @mtmdphd *DRAFT* Table Update: Nov 28, 2023 cc @grpetersen1 & @MyelomaTeacher @szusmani
1
2
10
@SusanBal9
Susan Bal
2 years
So many things to be grateful for but most thankful this year for my lil turkey! Happy Thanksgiving to all
0
0
6
@SusanBal9
Susan Bal
2 years
An impassioned talk by the eloquent @SagarLonialMD about how to get to CURE using available immunotherapies
0
1
9